Becton, Dickinson and Company $BDX Shares Bought by NEOS Investment Management LLC

NEOS Investment Management LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 44.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,656 shares of the medical instruments supplier’s stock after purchasing an additional 12,113 shares during the quarter. NEOS Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $7,422,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. RiverGlades Family Offices LLC acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $344,000. Oppenheimer Asset Management Inc. lifted its position in shares of Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after purchasing an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC boosted its holdings in Becton, Dickinson and Company by 88.2% during the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after purchasing an additional 2,715 shares during the last quarter. Finally, Belpointe Asset Management LLC bought a new position in Becton, Dickinson and Company in the third quarter valued at $650,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,416 shares of company stock valued at $675,557. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Up 3.1%

BDX opened at $182.82 on Thursday. The stock’s fifty day simple moving average is $198.01 and its 200 day simple moving average is $192.26. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $185.02. The stock has a market cap of $52.06 billion, a PE ratio of 29.82, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has authorized a stock buyback program on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley increased their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Citigroup lowered their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Jefferies Financial Group decreased their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.